Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. Its development programs also comprise Sapacitabine, a novel nucleoside analog that is orally available prodrug of CNDAC, which is in Phase 1/2 clinical trials to treat acute myeloid leukemia and myelodysplastic syndrome; and seliciclib, a CDK inhibitor that is in Phase 2 investigator-sponsored trials (IST) for Cushing's disease, as well as in Phase 1/2 IST for the treatment for advanced rheumatoid arthritis. The company has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey.
Cyclacel Pharmaceuticals Dividend Announcement
• Cyclacel Pharmaceuticals announced a annually dividend of $0.00 per ordinary share which will be made payable on 2016-08-01. Ex dividend date: 2016-07-13
• Cyclacel Pharmaceuticals's trailing twelve-month (TTM) dividend yield is -%
• Cyclacel Pharmaceuticals's payout ratio for the trailing twelve months (TTM) is -0.44%
Cyclacel Pharmaceuticals Dividend History
Ex-Div date | Dividend amount | Dividend type | Pay date |
---|---|---|---|
2016-07-13 | $0.00 | annually | 2016-08-01 |
Cyclacel Pharmaceuticals Dividend per year
Cyclacel Pharmaceuticals Dividend Yield
Cyclacel Pharmaceuticals current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Cyclacel Pharmaceuticals stock? Use our calculator to estimate your expected dividend yield:
Cyclacel Pharmaceuticals Financial Ratios
Cyclacel Pharmaceuticals Dividend FAQ
1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.
2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.
3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.
4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.
5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Place an order: Use the brokerage's trading platform to place an order to buy Cyclacel Pharmaceuticals stock.
Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.